Drug Profile
JNJ 54175446
Alternative Names: JNJ-54175446; JNJ-5446Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Janssen-Cilag
- Class Antidepressants; Azoles; Phenols; Pyridines; Pyrimidines
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 25 Jul 2022 JNJ 54175446 is still in phase II trials for Major depressive disorder (Adjunctive treatment) in United Kingdom (PO) (NCT04116606) (ISRCTN44411633) (EudraCT2018-001884-21)
- 05 Nov 2020 Janssen-Cilag reinitiates phase II trial in Major depressive disorder in United Kingdom (ISRCTN44411633) (NCT04116606)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Belgium (PO, Capsule)